67 related articles for article (PubMed ID: 21918971)
1. A dual-targeting antibody against EGFR-VEGF for lung and head and neck cancer treatment.
Zhang H; Yun S; Batuwangala TD; Steward M; Holmes SD; Pan L; Tighiouart M; Shin HJ; Koenig L; Park W; Rycroft D; Nannapaneni S; Wang Y; Chen ZG; Shin DM
Int J Cancer; 2012 Aug; 131(4):956-69. PubMed ID: 21918971
[TBL] [Abstract][Full Text] [Related]
2. BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth.
Boreddy SR; Nair R; Pandey PK; Kuriakose A; Marigowda SB; Dey C; Banerjee A; Kulkarni H; Sagar M; Krishn SR; Rao S; Ar M; Tiwari V; Alke B; Mv PK; Shri M; Dhamne C; Patel S; Sharma P; Periyasamy S; Bhatnagar J; Kuriakose MA; Reddy RB; Suresh A; Sreenivas S; Govindappa N; Moole PR; Bughani U; Tan SL; Nair P
Cancer Res; 2023 Jun; 83(11):1883-1904. PubMed ID: 37074042
[TBL] [Abstract][Full Text] [Related]
3. Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer.
Bauman JE; Ferris RL
Cancer; 2014 Mar; 120(5):624-32. PubMed ID: 24222079
[TBL] [Abstract][Full Text] [Related]
4. Construction of a Novel Bispecific Antibody to Enhance Antitumor Activity against Lung Cancer.
Yin W; Zhu J; Gonzalez-Rivas D; Okumura M; Rocco G; Pass H; Jiang G; Yang Y
Adv Mater; 2018 Dec; 30(51):e1805437. PubMed ID: 30345557
[TBL] [Abstract][Full Text] [Related]
5. Gold Nanoparticles Enhance the Tumor Growth-Suppressing Effects of Cetuximab and Radiotherapy in Head and Neck Cancer In Vitro and In Vivo.
Sato T; Kakei Y; Hasegawa T; Kashin M; Teraoka S; Yamaguchi A; Sasaki R; Akashi M
Cancers (Basel); 2023 Dec; 15(23):. PubMed ID: 38067400
[TBL] [Abstract][Full Text] [Related]
6. Cetuximab-Toxin Conjugate and NPe6 with Light Enhanced Cytotoxic Effects in Head and Neck Squamous Cell Carcinoma In Vitro.
Komatsu N; Kosai A; Kuroda M; Hamakubo T; Abe T
Biomedicines; 2024 Apr; 12(5):. PubMed ID: 38790935
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of cetuximab-immunoliposomes via a cholesterol-based membrane anchor for targeting of EGFR.
Pan X; Wu G; Yang W; Barth RF; Tjarks W; Lee RJ
Bioconjug Chem; 2007; 18(1):101-8. PubMed ID: 17226962
[TBL] [Abstract][Full Text] [Related]
8. Design and Evaluation of a Humanized Anti-EGFR huscFv Antibody Fragment in Combination With Metformin in A549 Cells
Solis-Estrada J; Arredondo-Espinoza E; Pioquinto-Ávila E; González-Cruz AO; Zarate X; Balderas-Rentería I
Anticancer Res; 2024 May; 44(5):1955-1962. PubMed ID: 38677771
[TBL] [Abstract][Full Text] [Related]
9. The use of epidermal growth factor receptor monoclonal antibodies in squamous cell carcinoma of the head and neck.
Russell JS; Colevas AD
Chemother Res Pract; 2012; 2012():761518. PubMed ID: 23150825
[TBL] [Abstract][Full Text] [Related]
10. DLX1008 (brolucizumab), a single-chain anti-VEGF-A antibody fragment with low picomolar affinity, leads to tumor involution in an in vivo model of Kaposi Sarcoma.
Eason AB; Sin SH; Shah M; Yuan H; Phillips DJ; Droste M; Shamshiev A; Dittmer DP
PLoS One; 2020; 15(5):e0233116. PubMed ID: 32407363
[TBL] [Abstract][Full Text] [Related]
11. Functional Profiling of Head and Neck/Esophageal Squamous Cell Carcinoma to Predict Cetuximab Response.
Selvan SR; Brichetti JA; Thurber DB; Botting GM; Bertenshaw GP
Cancer Biother Radiopharm; 2021 Nov; ():. PubMed ID: 34846938
[No Abstract] [Full Text] [Related]
12. Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy.
Sihver W; Pietzsch J; Krause M; Baumann M; Steinbach J; Pietzsch HJ
Pharmaceuticals (Basel); 2014 Mar; 7(3):311-38. PubMed ID: 24603603
[TBL] [Abstract][Full Text] [Related]
13. Inhaled delivery of cetuximab-conjugated immunoliposomes loaded with afatinib: A promising strategy for enhanced non-small cell lung cancer treatment.
Liu S; Chen D; Zhu X; Wang X; Li X; Du Y; Zhang P; Tian J; Song Y
Drug Deliv Transl Res; 2024 Feb; ():. PubMed ID: 38381317
[TBL] [Abstract][Full Text] [Related]
14. Targeted Polymer-Based Probes for Fluorescence Guided Visualization and Potential Surgery of EGFR-Positive Head-and-Neck Tumors.
Pola R; Böhmová E; Filipová M; Pechar M; Pankrác J; Větvička D; Olejár T; Kabešová M; Poučková P; Šefc L; Zábrodský M; Janoušková O; Bouček J; Etrych T
Pharmaceutics; 2020 Jan; 12(1):. PubMed ID: 31906300
[TBL] [Abstract][Full Text] [Related]
15. Engineered therapeutic antibodies with mannose 6-phosphate analogues as a tool to degrade extracellular proteins.
Daurat M; Gauthier C; El Cheikh K; Ali LMA; Morère E; Bettache N; Gary-Bobo M; Morère A; Garcia M; Maynadier M; Basile I
Front Immunol; 2024; 15():1273280. PubMed ID: 38533506
[TBL] [Abstract][Full Text] [Related]
16. Impact of Macrophages on the Interaction of Cetuximab-Functionalized Polyelectrolyte Capsules with EGFR-Expressing Cancer Cells.
Nifontova G; Kalenichenko D; Kriukova I; Terryn C; Audonnet S; Karaulov A; Nabiev I; Sukhanova A
ACS Appl Mater Interfaces; 2023 Nov; ():. PubMed ID: 37917654
[TBL] [Abstract][Full Text] [Related]
17. NIR Photodynamic Destruction of PDAC and HNSCC Nodules Using Triple-Receptor-Targeted Photoimmuno-Nanoconjugates: Targeting Heterogeneity in Cancer.
Bano S; Obaid G; Swain JWR; Yamada M; Pogue BW; Wang K; Hasan T
J Clin Med; 2020 Jul; 9(8):. PubMed ID: 32726945
[TBL] [Abstract][Full Text] [Related]
18. Direct Functionalization of Polysaccharide-Based Xylan Phenyl Carbonate Nanoparticles with Tumor Cell Specific Antibodies.
Bilemjian V; Lin Y; Wan W; Egri G; Huls G; Heinze T; Bremer E; Gericke M; Dähne L
Chembiochem; 2024 Mar; 25(5):e202300828. PubMed ID: 38236789
[TBL] [Abstract][Full Text] [Related]
19. Direct antitumor activity of bevacizumab: an overlooked mechanism?
Wang Z; Li J; Guo J; Wei P
Front Pharmacol; 2024; 15():1394878. PubMed ID: 38716237
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
